Gout

This is one of those satisfying diagnoses you can often make by simply watching the patient walk from the waiting room. But do we still feel confident if we are encouraged to start disease-modifying treatment after just one attack?

Gout is the most common inflammatory arthropathy, affecting 2.5% of adults in the UK.

Thinking is changing and, rather than being ‘episodic’, it is considered to be a chronic inflammatory arthropathy.

There have been a glut of new guidelines recently focusing on the management of gout. This article summarises the British Society of Rheumatology 2017 guideline (Rheumatology 2017;56:e1), endorsed by NICE. We also answer questions it raises.

These guidelines suggest significant changes to our practice.

Changes to management of gout: headlines

The UK British Society of Rheumatology suggests the following changes to our practice:

- Offer the option of uric acid-lowering treatment with allopurinol to ALL patients after their first attack of gout.
- Febuxostat is approved by NICE as a second-line choice but see below.
- Treat-to-target with regular up-titration of doses, aiming for a serum uric acid level of:
  - <300 micromol/L if tophi present until they resolve.
  - <360 micromol/L if no tophi/tophi resolved.
- Higher doses of allopurinol than we have traditionally used in primary care may be needed to achieve this.
- Co-prescribe colchicine 500mcg once or twice daily for 3–6m when initiating urate-lowering therapy to reduce the risk of acute attacks. NSAIDs + PPI can be used if colchicine is not tolerated.
- Start treatment for acute attacks as soon as possible.
- Assess and manage cardiovascular risk.

But what is the evidence behind these recommendations? And if we are going to start allopurinol after one attack, how can we be more confident in our diagnosis?

Diagnosis

There is an incomplete evidence base for the best way to diagnose gout.

Joint aspiration

The ‘gold standard’ method to diagnose gout is aspiration of synovial fluid with microscopy for crystals. But aspiration is technically difficult (and painful!). False negative results can be seen if the sample takes too long to reach the lab and this is a real issue in primary care.

Clinical diagnosis

In primary care, we usually make a clinical diagnosis (a survey of the Red Whale team suggests that none of us do joint aspirations, despite it being the gold standard).

- The typical history of gout is sudden-onset acute pain in one joint, peaking by 24–48h and then subsiding in 1–2w.
- 50–75% of the time it affects the 1st MTP.
- It can also affect the knee, wrist, fingers, ankles and midfoot.
- The main differentials are trauma, pseudogout or septic arthritis.

The dilemma we face

A systematic review concluded that synovial fluid analysis should be used where ‘clinical judgement indicates a diagnostic test is necessary’ – but what does this mean? (Ann Int Med 2017;166:52).

If we follow the 2017 management guideline and commit patients to lifelong allopurinol on the basis of one attack, we think we need to be pretty sure of our diagnosis.

A scoring system can improve accuracy of diagnosis

There is a primary care scoring system that does not require aspiration and that performs better than clinical judgement alone (Rheumatology 2015;54:609).
Note that this score includes serum uric acid. If you have historical uric acid measurements, these may be helpful, but we are not advocating testing during the attack because uric acid levels are often falsely LOW at this time. The ideal is to measure it 4–6w AFTER the attack. However, if you do measure uric acid during an attack AND it is raised, you have your answer.

<table>
<thead>
<tr>
<th>Features of presentation</th>
<th>If yes score:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male sex</td>
<td>2</td>
</tr>
<tr>
<td>Previous patient reported arthritis attack</td>
<td>2</td>
</tr>
<tr>
<td>Onset within 1d</td>
<td>0.5</td>
</tr>
<tr>
<td>Joint redness</td>
<td>1</td>
</tr>
<tr>
<td>1st MTP involvement</td>
<td>2.5</td>
</tr>
<tr>
<td>Hypertension or ≥1 cardiac disease (IHD/CVA/Stroke/PVD)</td>
<td>1.5</td>
</tr>
<tr>
<td>Serum uric acid &gt;350μmol/L</td>
<td>3.5</td>
</tr>
</tbody>
</table>

**Interpretation of scores**

- <4 points  Gout unlikely – consider alternative diagnosis
- 4–8 points This group are most likely to benefit from aspiration to establish the diagnosis
- ≥8 points  Gout highly likely: start empiric treatment

- Clinical assessment has a PPV of 64% and an NPV of 87%.
- The tool offers a PPV of 87% and an NPV of 95%.
- Reminder: the PPV (positive predictive value) is the proportion of the people who test positive who actually have the disease; the NPV (negative predictive value) is the proportion of people told they don’t have the disease who really don’t have it.

Most patients we treat for gout would score 8 or more points. The ones that can trip us up are first presentations in a knee, ankle or wrist joint. Septic arthritis may be on our differential here, and a secondary care assessment and joint aspiration would be appropriate. Otherwise, if the patient would consider urate-lowering treatment, I may ask the rheumatology on-call team whether ultrasound-guided aspiration was an option.

**Investigations**

Serum uric acid levels may be falsely low during an attack. At 4–6w after the acute attack, organise:

- U&E.
- Lipids.
- HbA1c.
- Uric acid.

Review results with patient and calculate and act on QRISK.

Now, let’s return to the guideline, which is endorsed by NICE.

<table>
<thead>
<tr>
<th>UK British Society of Rheumatology Gout Management Guideline (Rheumatology 2017:56:1)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Management of acute attacks</strong></td>
</tr>
<tr>
<td>- Offer all patients high quality written information, e.g. Patient UK, ARC (see Useful websites below)</td>
</tr>
<tr>
<td>- Start treatment as soon as possible after an acute attack to minimise joint impact (although remember you need to wait 4w before measuring serum urate as results may be falsely low during an attack)</td>
</tr>
<tr>
<td>- For acute attacks, all treatments are similarly effective: choice will be based on patient preferences and co-morbidities</td>
</tr>
<tr>
<td>- Uric acid levels can be falsely low during an attack and should NOT be measured until 4w after the acute episode</td>
</tr>
</tbody>
</table>

**First line choices**

NSAID + PPI
or
Colchicine 500mcg 2–4 times daily

**Second line choices (where contraindications or intolerances exist)**

Oral prednisolone, e.g. 35mg once daily for 5d
or
Intra-articular or intra-muscular steroid

**Non-pharmacological treatments**

Rest, elevation, ice, bed cages

**Management of co-morbidities**

Gout commonly co-exists with metabolic syndrome. Screen affected individuals annually for:

- Hypertension
What is the evidence for treating after one attack?

There is a clear causative link between raised serum uric acid and:

- Gout.
- Urate renal stones.

There were five other associations: with hypertension, heart failure, diabetes, CKD and death from CHD. The strength of evidence was not sufficient to prove causation (BMJ 2017;357:j2376).

The guidance to offer treatment after one attack is controversial. There is an absence of evidence to support it (DTB 2018;56(1):9).

**Joint outcomes**

The guideline recommends starting urate-lowering treatment after one attack. This is a change in practice based on Delphi consensus process (expert opinion). The rationale is:

- Chronic crystal deposition can be seen at the first attack of gout and likely predates symptoms.
- These crystals lead to ongoing joint damage and chronic arthritis.

The existing evidence base:

- Strongly supports use of urate-lowering drugs in the presence of 2 or more attacks, tophi or impaired renal function (eGFR <60).
- Based on imperfect studies, a Cochrane review comparing allopurinol (at doses of 100–300mg) with placebo concluded that allopurinol probably does not reduce acute attacks – at best, an absolute risk reduction of 4% is seen. It does reduce serum uric acid (Cochrane 2014;CD006077).

**Cardiovascular outcomes**

Patients diagnosed with gout are at increased risk of metabolic syndrome. There is an absence of evidence that urate-lowering treatment alters that risk in a meaningful way (BMJ 2017;357:j2376).

- Meta-analyses have shown that urate-lowering treatment has marginal benefits in improving surrogate markers of cardiovascular disease, e.g. blood pressure, endothelial function and renal function.
- There have never been any studies that have shown that urate-lowering treatment reduces the risk of important endpoints like heart attack, stroke and mortality.

*This means that we should manage the cardiovascular risk as for any other patient, with lifestyle interventions, management of hypertension and lipids, etc. We should also discuss the advantages and disadvantages of long-term urate-lowering treatment and be honest about the current limitations of the evidence.*

**After a first attack, how likely is a second attack?**

The guideline cites evidence which suggests that 62% of patients with gout will have a second attack within 12m.

The risk increases with increased levels of serum urate: at levels of >500 micromol/L, the risk is almost 100%.

**What is the evidence for treating-to-target?**

A systematic review addressed this and concluded (Ann Int Med 2017;166:37):

- There is a logical appeal in treating-to-target and observational evidence suggests it is beneficial.
- There are no robust RCTs comparing treating-to-target with ‘usual care’ or ‘treating-to-symptom control’.

The authors and editorial conclude that this is an important question to answer; this next study starts to address this issue.

**How should we organise gout care?**

*Nurse-led (or pharmacist-led) clinics. Probably.*

Gout is a long-term condition. In keeping with other long-term conditions, a UK-based RCT study demonstrated that nurse-led care can be more clinically-effective and cost-effective than GP-led care (Lancet 2018;392;1403).

More than 500 patients with gout were assigned to receive nurse-led care or ‘usual’ GP-led care. The nurses were research nurses who had been trained in the management of gout. They spent more time on patient education and individualising explanations. There will be a follow-up study implementing the same protocol for practice nurses.

Patients were followed-up for 2 years.

<table>
<thead>
<tr>
<th>Outcome measures at 2 years</th>
<th>Nurse-led care (% patients achieving outcome)</th>
<th>Usual care (% patients achieving outcome)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum urate &lt;360 micromol/L</td>
<td>95%</td>
<td>30%</td>
</tr>
<tr>
<td>Serum urate &lt;300 micromol/L</td>
<td>88%</td>
<td>17%</td>
</tr>
<tr>
<td>Taking urate-lowering therapy</td>
<td>96%</td>
<td>56%</td>
</tr>
</tbody>
</table>
Note that in the nurse-led group, the risk of having 2 or more flares was greater in year 1, likely reflecting up-titration of urate-lowering therapy.

Crude cost-effectiveness analysis suggests that at year 2, it would cost £5066 per QALY gained, modelled to be £286 by year 3 (so a big upfront cost, but below the NICE threshold of £20 000/QALY), with the potential to save costs by year 5.

Similar benefits have been seen in smaller US studies of pharmacist-led care.

So, nurse-led care led to better patient outcomes but at a greater cost. Longer-term follow-up will tell us if this initial investment is offset by later financial savings.

Allopurinol vs. febuxostat for cardiovascular outcomes

A recent pharma-sponsored, non-inferiority, double-blind RCT of more than 6000 patients with gout AND cardiovascular disease compared cardiovascular outcomes in patients on febuxostat with patients on allopurinol (NEJM 2018;378:1200).

The authors pre-specified that febuxostat would be considered ‘non-inferior’ if it was \(\leq 1.3\times\) worse than allopurinol for cardiovascular outcomes (a composite endpoint of CV death and other CV events).

The results show:

- There were high discontinuation and drop-out rates (around 50%) over the course of the trial in both groups.
- The primary event rate (cardiovascular events and cardiovascular deaths) was high in both groups – more than 10.8% in the febuxostat group and 10.4% in the allopurinol group over 5y.
- The authors of the study concluded that febuxostat was ‘non-inferior’; the rate of composite cardiovascular events and deaths was similar and within the non-inferiority margin.

However:

- There was a statistically-significant increase in all-cause and cardiovascular mortality in the febuxostat group compared with allopurinol:
  - Cardiovascular mortality HR 1.34 (CI 1.03–1.73).
  - All-cause mortality HR 1.22 (CI 1.01–1.47).

This supports NICE’s view that allopurinol is the first-line choice for the management of gout, and febuxostat should remain a second-line drug. The UK SPC recommends that febuxostat is not used for patients with ischaemic heart disease or congestive heart failure.

On the basis of this study, in July 2019 the MHRA recommended that we should avoid treatment with febuxostat in patients with pre-existing major cardiovascular disease, e.g. history of MI, angina or stroke, unless no other therapy option is appropriate.

Doses of allopurinol in impaired renal function

A DTB review on the management of gout included a helpful table of recommended starting doses of allopurinol in renal impairment. In these patients, serum uric acid and renal function should be monitored every 3m in the first year, then annually. Advice from renal physicians may be needed for dose escalation (DTB 2018;56(1):9).

<table>
<thead>
<tr>
<th>eGFR (ml/min/1.73m2)</th>
<th>Allopurinol starting dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;5</td>
<td>50mg weekly</td>
</tr>
<tr>
<td>5–15</td>
<td>50mg twice weekly</td>
</tr>
<tr>
<td>16–30</td>
<td>50mg every 2d</td>
</tr>
<tr>
<td>31–45</td>
<td>50mg daily</td>
</tr>
<tr>
<td>46–60</td>
<td>50mg and 100mg alternate days</td>
</tr>
<tr>
<td>61–90</td>
<td>100mg daily</td>
</tr>
</tbody>
</table>

Antihypertensives and gout
Which is the best antihypertensive for patients with gout?

A UK-based study of over 24,000 patients with gout used the CPRD to answer this question (BMJ 2012;344:d8190). It looked at the relative risk of gout associated with the use of different antihypertensive drugs:

<table>
<thead>
<tr>
<th>Antihypertensives that lower gout attack risk</th>
<th>Antihypertensives that increase gout attack risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calcium channel blockers</td>
<td>Diuretics</td>
</tr>
<tr>
<td>Losartan</td>
<td>Beta-blockers</td>
</tr>
<tr>
<td></td>
<td>ACE inhibitors</td>
</tr>
<tr>
<td></td>
<td>Non-losartan ARBs.</td>
</tr>
</tbody>
</table>

Something to consider when you are reviewing your hypertensive patients with gout, particularly if they are having recurrent attacks?

Hyperuricaemia and risk of neurodegenerative diseases

A number of studies have suggested that hyperuricaemia may offer some protection against dementia and Parkinson’s disease (BJGP 2017;67:284). This is an association and was NOT demonstrated in the BMJ umbrella review discussed above.

It is not known whether lowering urate levels in the context of gout increases the risk of these conditions. As a precaution, the guideline suggests that urate levels should not be left significantly below 300 micromol/L once tophi have resolved (BJGP 2017;67:284).

Diet vs. genetics

There is a common perception that gout and raised serum urate are dietary. A recent meta-analysis of five cohort studies including men and women of European ancestry who had never had gout challenges this perception (BMJ 2018;363:k3951).

- It identified an association between some foods (alcohol- and sugar-containing beverages, meat, poultry, potatoes) and elevated serum urate levels.
- None of these foods explained even 1% of variation in urate levels.
- Genetic susceptibility had a much larger impact on high serum urate levels than variations in diet.

However, the authors acknowledge that while genetics cannot be changed, diet can.

The DASH diet

The DASH (Dietary Approach to Stop Hypertension) diet is based on a high intake of fruit, veg, legumes, nuts, low-fat dairy and whole grains, and a low intake of salt, sweetened drinks, and red and processed meats. It has been demonstrated in RCTs to lower serum urate.

A well-designed, prospective cohort study followed more than 40,000 men who had never had gout for 26 years. It looked prospectively at the impact of the DASH diet compared with a typical western diet on the risk of developing gout for the first time (BMJ 2017;357:j1794).

- Individuals who followed a DASH-type diet had a 30% lower risk of developing gout.
- A dose–response effect seen.

Sugary drink consumption

A prospective cohort study of more than 46,000 men looked at the association between fructose-containing sugary drink consumption and the risk of gout (BMJ 2008;336:309).

It found that:

- Gout attacks were more likely in men consuming fructose-containing soft drinks, and that this effect was dose dependent.
- The risk started to accumulate at 5–6 servings per week. If 2 servings per day were consumed, a man had double the risk of gout compared with men who do not consume sugary soft drinks.
- There was no association with diet soft drinks.

It is reasonable to encourage a DASH-type diet, and to ask about fructose consumption and encourage men with gout to reduce this.
Gout

- Use a diagnostic tool rather than clinical judgement alone.
- Discuss urate-lowering therapy with all patients diagnosed with gout.
- If using urate-lowering therapy, treat-to-target – this may need higher doses of allopurinol.
- Offer all an annual CV risk assessment and HbA1c.
- Use allopurinol first line and febuxostat second line.
- If using febuxostat, it is essential to co-prescribe colchicine for 6m.

Audit your care of gout patients – search for all gout patients on your list.

- What proportion are on urate-lowering therapy?
- Of those on urate-lowering therapy, how many are hitting target levels of uric acid?
- How many have an up-to-date cardiovascular risk assessment?
- How could you review this and re-audit?
- Could you offer standby courses of treatment for management of acute attacks?

A useful patient information leaflet can be found here:
http://tinyurl.com/GPU-Gout-leaflet

A PDF of the primary care gout diagnosis tool can be found here:
www.mdcalc.com/acute-gout-diagnosis-rule

A link to a patient information leaflet about the DASH diet:
https://tinyurl.com/GPU-DASH-diet

We make every effort to ensure the information in these articles is accurate and correct at the date of publication, but it is of necessity of a brief and general nature, and this should not replace your own good clinical judgement, or be regarded as a substitute for taking professional advice in appropriate circumstances. In particular check drug doses, side-effects and interactions with the British National Formulary. Save insofar as any such liability cannot be excluded at law, we do not accept any liability for loss of any type caused by reliance on the information in these articles.
About Versus Arthritis

In 2017, Arthritis Research UK and Arthritis Care joined forces so that we could achieve more for people with arthritis. In September 2018, we became Versus Arthritis.

Join our professional network and become part of a growing community working together to change the face of MSK care. We'll keep you connected with the latest developments in MSK health and care, you’ll receive bulletins containing practical tips, and development opportunities as well as the latest Versus Arthritis patient information. https://www.versusarthritis.org/about-arthritis/healthcare-professionals/the-professional-network/

For you…

• If you’re looking to gain some hands-on, practical training in MSK then check out our Core Skills in Musculoskeletal Care. Core Skills is designed specifically for GPs to help you feel confident and knowledgeable in managing patients with MSK conditions. Our e-learning is free to access and then if you want to build on this with some hands-on learning then come along to one of our practical workshops running across the UK. Led by a team of GPs with special interest in MSK, they’ll help you get the basics right in examination and consultation skills. https://www.versusarthritis.org/about-arthritis/healthcare-professionals/core-skills-in-musculoskeletal-care/

• We provide all UK medical schools with accessible, relevant, evidence based educational resources. Our study guide and series of educational videos support medical students and healthcare professionals to build their skills and confidence in assessing people with musculoskeletal conditions in order to deliver effective care. https://www.versusarthritis.org/about-arthritis/healthcare-professionals/clinical-assessment-of-the-musculoskeletal-system/

• Through our MSK champions programme we are aiming to create leaders of change who are committed to change in musculoskeletal care. Applications open again from March 2020. https://www.versusarthritis.org/about-arthritis/healthcare-professionals/msk-champions/

For your patients…

• Order or download patient information leaflets free of charge https://www.versusarthritis.org
• Encourage your patients to call the free Versus Arthritis helpline https://www.versusarthritis.org/get-help/helpline/
• Signpost to our arthritis virtual assistant, a 24/7 tool that provides fast, easy to access information https://www.versusarthritis.org/get-help/arthritis-virtual-assistant/
• Explore our online community which will connect your patients with real people who share the same everyday experiences https://arthritiscareforum.org.uk
• Connect to local groups and find out what’s going on where your patients are https://www.arthritiscare.org.uk/in-your-area
• Find useful information for your patients on gout here: https://www.versusarthritis.org/about-arthritis/conditions/gout/ https://www.versusarthritis.org/media/1253/gout-information-booklet.pdf

Join the growing community of healthcare professionals today and, together we can push back against arthritis. https://www.versusarthritis.org/about-arthritis/healthcare-professionals/the-professional-network/

For more information contact professionalengagement@versusarthritis.org
The GP Update Course with 12 CPD hours

The Brand New Mental Health Update Course
The GP Update Course

Now with 6 extra hours of additional online content!

Staying up to date with the latest evidence is just one of the many balls we have to juggle in primary care, so we’ve added six extra hours of video learning to our GP Update Course – to help you keep those balls up in the air!

You’ll get all the great benefits of a Red Whale course:

• 6 hours of teaching worth 6 CPD credits.
• A copy of the GP Update Handbook to take home.
• 12 months free access to www.gpcpd.com (our online handbook and in-consultation search tool).

And with ‘GP Update Extra’ you’ll also get:

• 6 additional hours (and 6 more CPD credits) of Red Whale video content to watch online!
• Includes level 3 adult and child safeguarding options to share with your team.

The GP Update Extra video content is delivered by the same great GP presenters who run our courses and you can stream it anytime, on any device, for 12 months after you attend the course, giving you a total of at least 12 CPD credits!

What can you expect from the extra content? A heap of time-saving tools and guides to make life a bit easier...

Some days it seems like whichever way we look, there are more balls being thrown at us. GP Update Extra has been designed to make it easier to keep them in the air! We will cover current issues that present challenges in our day-to-day lives, or make meeting some CPD requirements seem like an impossible task!

• Level 3 adult and child safeguarding training - 2 hours of training which we guarantee is more enjoyable than an online learning module. Do it with your team to increase it to 4 hours and fulfil the participatory requirements.
• An urgent care and minor injuries update - we cover some big topics to bring those stress levels down.
• Strategies to deal with those rogue blood test results that linger in our inbox.
• How to get the most impact out of new roles in the primary care team.
• New cancer treatments with BIG implications for primary care.
• Ways to help patients embrace lifestyle advice. Yes really! We’ll share resources and communication strategies that really help. Plus we’ll look at motivational interviewing and the GRIN model.

Join us this spring for The GP Update Course, where we’ll get you up to date, keep you juggling those balls* and bag you 12 CPD credits!

*No actual juggling tuition is provided. Sorry.
GP Update Course

Struggling to keep up with all the guidelines and evidence? Not sure which bits should change our practice? Relevant for all primary care clinicians, and designed to make our lives easier with immediate practice change impact.

On our challenging and fun one day course we cover:
• Recent hot topics from primary care
• Common clinical conundrums, using the best evidence available
• Oodles of great material for appraisal and revalidation and preparation for AKT and CSA.

Mental Health Update Course

Mental health issues impact on so many of our consultations. But giving meaningful support in a 10 minute consultation can sometimes feel like an overwhelming challenge.

Our one-day course covers:
• The ‘mental health condition families’ and how to use them to make a confident diagnosis
• Creating new narratives to engage with people with a range of key mental health disorders
• Navigating different therapy options and drug dilemmas
• ‘Microskills’ like behavioural activation, problem solving and self-compassion that we can start using with patients the next day!
• How we can look after ourselves as health professionals.

2020 Prices: All courses £225 for GPs, £195 for non GPs

Check out our website for more courses running later in the year and save £70 when you book 3 courses in 2020*

*Use discount code 3BUNDLE2020 when you book online or when you call us on 03330 093 090. All courses must be taken by the same delegate and in the same calendar year. Only one promotion code can be used per booking.

To book go to www.gp-update.co.uk or call us on 03330 093 090
Red Whale Deep Dives give you:

• A chance to take a ‘deep dive’ into important, difficult or controversial topics in more detail.
• At least 3 ‘microlearning segments’ per webinar – or Quick Dips as we like to call them – perfect for fitting into your busy daily routine.
• Cases, quizzes and polls to test your knowledge.
• Great resources to download and use back at the surgery the next day.
• The most relevant information for primary care, delivered by the Red Whale team.

How it works

• You choose which webinars you want access to and buy them online.
• Each webinar lasts one hour and you can either watch them live on the dates and times shown or on demand.
• You’ll also have access to lots of useful resources to download and use straightaway in your practice!
• Get each webinar at an introductory discounted price of £20 per webinar (normally £25!).

Where do I sign up?

Visit gp-update.co.uk/deepdives to find out more about each webinar and sign up. After purchase, watch on-demand webinars straight away and get reminder emails for your upcoming live webinars.

What’s on in 2019?

AVAILABLE ON DEMAND NOW!

- Inflammatory bowel disease: It’s all diarrhoea isn’t it? 25 June 8pm
- The menopause laid bare 18 July 8pm
- Anxiety: A Cinderella condition? 10 September 8pm
- Diabetes in remission: A story of hope? 22 October 8pm
- Contraception laid bare 14 November 8pm
- Emergencies in primary care 12 December 8pm
- The best of 2019: Our top 10 practice-changing points

Penrith Roadshow 2020

Join us in The Lakes from Wednesday 1st July to Saturday 4th July 2020 and choose from five of our most popular update courses! And get £100 off when you book 4 courses, using the code 4PENRITH2020*. For more information and to book, go to: www.gp-update.co.uk/deepdives

*Use discount code 4PENRITH2020 when you book online or when you call us on 03330 093 090. Discount is only available for Penrith Roadshow dates and all courses must be taken by the same delegate and booked at the same time. Only one promotion code can be used per booking.

Deep Dives WEBINAR SERIES

Catch our Deep Dives webinars live every month, or watch on demand afterwards – whenever it suits you! Join us while we dive deep into those trickier areas of primary care – answering your conundrums and helping you change your practice. Deep Dives are a series of one-hour webinars, worth 1 CPD point each, with an introductory price of £20 (normally £25).

Check out our 2020 Deep Dives Webinars, available to book online:

- Thursday 27 February 8pm
  • Men’s health laid bare

- Wednesday 4 March 8pm
  • Problem periods laid bare

Now available on demand:

- Making multidisciplinary primary care work: making the most of your ARRS